Pulse Biosciences, Inc.: operating income or loss
Operating income or loss for Pulse Biosciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Pulse Biosciences, Inc. financial histories
What this measure means
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
Exact concept: us-gaap:OperatingIncomeLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -76,939,000 | USD | 2026-02-19 | 10-K · 0001437749-26-004724 |
| 2024-01-01 | 2024-12-31 | -56,257,000 | USD | 2026-02-19 | 10-K · 0001437749-26-004724 |
| 2023-01-01 | 2023-12-31 | -43,574,000 | USD | 2025-03-31 | 10-K · 0001437749-25-009932 |
| 2022-01-01 | 2022-12-31 | -58,057,000 | USD | 2024-03-28 | 10-K · 0001437749-24-009815 |
| 2021-01-01 | 2021-12-31 | -63,014,000 | USD | 2023-03-31 | 10-K · 0001437749-23-008846 |
| 2020-01-01 | 2020-12-31 | -49,965,000 | USD | 2023-03-31 | 10-K · 0001437749-23-008846 |
| 2019-01-01 | 2019-12-31 | -47,954,000 | USD | 2022-03-31 | 10-K · 0001625101-22-000016 |
| 2018-01-01 | 2018-12-31 | -37,545,000 | USD | 2021-03-12 | 10-K · 0001625101-21-000014 |
| 2017-01-01 | 2017-12-31 | -25,567,000 | USD | 2020-03-16 | 10-K · 0001625101-20-000011 |
| 2016-01-01 | 2016-12-31 | -9,518,000 | USD | 2019-03-14 | 10-K · 0001625101-19-000008 |
| 2015-01-01 | 2015-12-31 | -4,468,000 | USD | 2018-03-16 | 10-K · 0001625101-18-000012 |
Related financial histories
- Pulse Biosciences, Inc.: total assets
- Pulse Biosciences, Inc.: total liabilities
- Pulse Biosciences, Inc.: stockholders equity
- Pulse Biosciences, Inc.: cash and cash equivalents
- Pulse Biosciences, Inc.: net income or loss
- Pulse Biosciences, Inc.: operating cash flow
- Pulse Biosciences, Inc.: capital expenditure payments
- Pulse Biosciences, Inc.: contract revenue excluding tax
- Pulse Biosciences, Inc.: financing cash flow
- Pulse Biosciences, Inc.: investing cash flow
- Pulse Biosciences, Inc.: retained earnings or deficit
- Pulse Biosciences, Inc.: basic weighted-average shares
- Pulse Biosciences, Inc.: basic earnings per share
- Pulse Biosciences, Inc.: income tax expense or benefit
- Pulse Biosciences, Inc.: net property, plant and equipment
- Pulse Biosciences, Inc.: share-based compensation expense
- Pulse Biosciences, Inc.: current assets
- Pulse Biosciences, Inc.: current liabilities
- Pulse Biosciences, Inc.: current accounts payable
- Pulse Biosciences, Inc.: net finite-lived intangible assets
- Pulse Biosciences, Inc.: net current accounts receivable
- Pulse Biosciences, Inc.: operating expenses
- Pulse Biosciences, Inc.: net inventory
- Pulse Biosciences, Inc.: cost of revenue
- Pulse Biosciences, Inc.: research and development expense
Inspect the source
- Entity
- Pulse Biosciences, Inc. / CIK 0001625101
- Captured
- 2026-09-21T17:21:59.611Z
- SEC response SHA-256
da48cc0d883956212e47225d4223bed26303a7cc28fc03877b3cc57d93451443
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001625101.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))